Facing the Challenges in Vaccine Upstream Bioprocessing * Integrated Continuous Manufacturing of Biologics: Trends in the Field technology providers and biomanufacturers-I think it is only a matter of time before we see a continuous process implemented at pilot scale (e.g., for production of a biotherapeutic for use in clinical trials), and then ultimately, at manufacturing scale. Dr. Pentia: It is still early [for many companies to consider] continuous biomanufacturing. The idea only started to be taken seriously approximately five years ago. The industry is still trying to understand where it is appropriate and how to fully control continuous manufacturing at large scale (tens of products are already produced in perfusion at commercial scale). I would not say there are too few manufacturers that are exploring this-it might be more accurate to say that every manufacturer is considering this approach, but some are further advanced than others, while others are just in the conceptual phase. n 22 | GENengnews.comhttp://www.GENengnews.com